Cabozantinib is an oral small-molecule multitargeted tyrosine kinase inhibitor 
(TKI) that may confer an advantage over other TKIs that target a single 
receptor. It was approved by the U.S. Food and Drug Administration for the 
treatment of both advanced renal cell carcinoma and progressive metastatic 
medullary thyroid cancer, and it is being investigated for a wide array of other 
malignancies. Rationale for use, clinical trial data, and current 
recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate 
cancer, hepatocellular cancer, and lung cancer are detailed in this article. 
Common adverse events are reviewed, and management strategies for select adverse 
events are discussed. Implications for contemporary practitioners are also 
provided because use of this novel agent is likely to increase as more studies 
are completed.